Status:
COMPLETED
Improvement of Compliance for High Doses of EPA Amongst Patients With Colorectal Cancer
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Rigshospitalet, Denmark
Conditions:
Compliance
Abdominal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Several studies indicate beneficial effects of eicosapentanoic acid (EPA) on cancer cachexia. However, compliance is generally low. This case control study is conducted in order to investigate if comp...
Detailed Description
Patients with abdominal cancer in active chemotherapeutic were allocated to either EPA in an oral nutritional drink (commercial) or capsules with fish oil. The dose of EPA was the same in both groups,...
Eligibility Criteria
Inclusion
- Patients receiving chemotherapy on Rigshospitalet due to colorectal cancer
- Not terminally ill
- Subjects must be18 years of age (or older)
Exclusion
- Subjects who do not read/speak/understand Danish
- Familial hypercholesterolemia
- Predialytic patients (GFR \< 15 ml/min/1,73 m2 or creatinine ≥ 500 mmol/L)
- Use of blood thinners
- Bleeder's disease
Key Trial Info
Start Date :
May 18 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2018
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT03751384
Start Date
May 18 2015
End Date
November 10 2018
Last Update
November 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100